| abstract |
The present invention relates to the use of compounds of formula I or their pharmaceutically acceptable salts, MET, VEGFR2, and ROS1 inhibitors, to patients, particularly patients with lung adenocarcinoma, more specifically SLC34A2. -Treating cancer in a patient who is non-small cell lung cancer positive for ROS1, CD74-ROS1 or FIG-ROS1 fusion gene. Lung cancer is the leading cause of cancer-related deaths worldwide. Recent developments in targeted therapy have led to a paradigm shift in the treatment of small cell lung cancer (NSCLC). |